Loading
Darolutamide is an AR blocker that barely enters the brain, so it causes fewer falls and cognitive side effects; it is approved with and without chemotherapy.
Darolutamide is a structurally distinct androgen receptor antagonist with low blood-brain-barrier penetration and activity against the AR F877L resistance mutation. Because little drug reaches the brain it causes fewer falls, fatigue and cognitive side effects than enzalutamide, which matters for older men and those on many medicines. ARAMIS (nmCRPC) showed an overall survival benefit; ARASENS proved triplet therapy with ADT plus docetaxel in mHSPC (OS HR 0.68, 4-year OS 62.7% versus 50.4%); ARANOTE supported the 2025 approval with ADT alone in mHSPC. Whether all men with metastatic hormone-sensitive disease need the chemotherapy component, or only those with high-volume disease, is still argued. For a newcomer, darolutamide is the AR blocker that barely enters the brain, approved with and without chemotherapy.
Structurally distinct AR antagonist, low blood-brain-barrier penetration, active against AR F877L. Connects to Androgen receptor.
1.Darolutamide acts on Androgen receptor, the hormone receptor or the enzyme that makes the hormone.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Oral, self-administered, so it is a Part D drug: covered through a stand-alone Part D plan or Medicare Advantage drug benefit, usually on the specialty tier with 25 to 33% coinsurance until the annual cap ($2,000 in 2025, $2,100 in 2026).
Covered for FDA-labelled and NCCN-listed uses, but almost always behind prior authorisation confirming diagnosis, biomarker and line of therapy; dispensed through a specialty pharmacy.
Part D out-of-pocket capped at $2,000 (2025) / $2,100 (2026). Medicare patients cannot use manufacturer co-pay cards; charity funds (PAN, HealthWell, CancerCare) and the Extra Help subsidy are the routes.
Sources: Medicare.gov: Drug coverage (Part D) · Medicare.gov: Costs for Medicare drug coverage (annual out-of-pocket cap). Not medical or financial advice; verify with your plan.
Sources: NICE TA660 · SMC advice: darolutamide. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
| Region | Year | Indication |
|---|---|---|
| US | 2019 | Non-metastatic CRPC |
| US | 2022 | mHSPC with docetaxel (ARASENS) |
| US | 2025 | mHSPC with ADT alone (ARANOTE) |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Triplet therapy with darolutamide is a standard for fit men with metastatic hormone-sensitive prostate cancer, particularly high-volume disease; PEACE-1 showed the same with abiraterone.
Darolutamide is often preferred in older men or those with fall or cognitive concerns because of its favourable tolerability among the three approved agents.
Query for this drug: (TITLE:"Darolutamide" OR ABSTRACT:"Darolutamide" OR TITLE:"Nubeqa" OR ABSTRACT:"Nubeqa") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Darolutamide, not a curated reading list.
Shares Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer, AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01), Disease volume (CHAARTED high-volume versus low-volume) and LATITUDE risk, PSA kinetics: PSA doubling time and PSA density.
Shares ARAMIS, Non-metastatic castration-resistant prostate cancer, Prostate cancer drugs in England: what NICE recommends, and what it refuses, Androgen deprivation & AR pathway inhibitors.
Shares mCRPC and mHSPC (castration-resistant vs hormone-sensitive prostate cancer), Prostate cancer (KEGG map), Androgen receptor signalling, Metastatic hormone-sensitive prostate cancer.
Shares ARAMIS, Non-metastatic castration-resistant prostate cancer, Prostate cancer drugs in England: what NICE recommends, and what it refuses, Androgen deprivation & AR pathway inhibitors.
Shares mCRPC and mHSPC (castration-resistant vs hormone-sensitive prostate cancer), Prostate cancer drugs in England: what NICE recommends, and what it refuses, Hormonal therapy roadmap: removing the ovaries → tamoxifen → oral degraders switched by a blood test, Metastatic hormone-sensitive prostate cancer.
Shares Prostate cancer drugs in England: what NICE recommends, and what it refuses, Androgen receptor signalling, Hormonal therapy roadmap: removing the ovaries → tamoxifen → oral degraders switched by a blood test, Metastatic hormone-sensitive prostate cancer.
Shares TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in , Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer, AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01), Disease volume (CHAARTED high-volume versus low-volume) and LATITUDE risk.
Shares ARASENS, Hormonal therapy roadmap: removing the ovaries → tamoxifen → oral degraders switched by a blood test, Metastatic hormone-sensitive prostate cancer, Androgen deprivation & AR pathway inhibitors.